I'm with ya Fuzz ... good to see, but "yeah yeah yeah" ...

I mean it is good to see "something" positive, with continued validation on the future potential of the science and therapeutics within the market. But, how long can this venture keep burning cash without inflows, and especially enough money and support to develop this science??

And what happened with the Sheik? Revenues in 2022? The 6 million ABL pills we were about to sell to India? Morocco and the ME development partnership? ... the list goes on ... and on ... and on.

Tons of science interest. No business or development interest. And no money. And no urgency.

Again, I think the May/June timeframe may provide some more clues about what lies ahead, and intentions, and who is on board (or not) with seeing it through toward success of one type or another.

With the IP at risk, I suppose that Don and/or other large interested stakeholders could probably come up with $6mm on their own though, if push comes to shove to preserve the IP and future opportunity. But, realistically, beyond the debenture/IP issue, RVX/ABL needs a serious cash infusion, partner, or sale. Just seems like it needs to happen soon, and May/June may at least provide some clues if not answers.